121 related articles for article (PubMed ID: 7841047)
1. The biological activity of cisplatin and dibromodulcitol in combination therapy.
Jeney A; Kovalszky I; Rásó E; Durand RE; Fürész J; Lapis K
Br J Cancer; 1995 Feb; 71(2):317-21. PubMed ID: 7841047
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of pirarubicin and epirubicin in combination with doxifluridine and cisplatin against mouse P388 leukemia.
Agata N; Mase T; Izumi H; Hirano S; Iguchi H; Tone H; Takeuchi T
Cancer Biochem Biophys; 1995 Nov; 15(2):95-101. PubMed ID: 8590441
[TBL] [Abstract][Full Text] [Related]
3. [Experimental evaluation of synergism of cisplatin with L-lysine-alpha-oxidase].
Pokrovskiĭ VS; Lukasheva EV; Treshchalina EM
Vopr Onkol; 2014; 60(1):90-3. PubMed ID: 24772623
[TBL] [Abstract][Full Text] [Related]
4. Different interaction of cisplatin and etoposide on in vivo and in vitro tumor systems.
Soranzo C; Pratesi G; Zunino F
Anticancer Drugs; 1990 Oct; 1(1):23-8. PubMed ID: 2131031
[TBL] [Abstract][Full Text] [Related]
5. [Combined effect of CDDP with various types of antitumor drugs against P 388 leukemia].
Uchida T; Nishikawa K; Shibasaki C; Okamoto K; Arakawa M; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2275-82. PubMed ID: 2735770
[TBL] [Abstract][Full Text] [Related]
6. Reduced antineoplastic activity in mice of cisplatin administered with high salt concentration in the vehicle.
Aamdal S; Fodstad O; Kaalhus O; Pihl A
J Natl Cancer Inst; 1984 Sep; 73(3):743-52. PubMed ID: 6590919
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemia.
Vannozzi MO; Ottone M; Mariggiò MA; Cafaggi S; Parodi B; Cilli M; Lindup E; Viale M
Anticancer Res; 2003; 23(2B):1509-16. PubMed ID: 12820417
[TBL] [Abstract][Full Text] [Related]
8. [Combination effects of etoposide with other antitumor drugs in vitro and in vivo].
Nishikawa K; Kusama K; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1989 Dec; 16(12):3739-45. PubMed ID: 2596858
[TBL] [Abstract][Full Text] [Related]
9. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
Li LH; DeKoning TF; Wallace TL
Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
[TBL] [Abstract][Full Text] [Related]
10. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo.
Shirasaka T; Shimamoto Y; Ohshimo H; Saito H; Fukushima M
Cancer Chemother Pharmacol; 1993; 32(3):167-72. PubMed ID: 8500219
[TBL] [Abstract][Full Text] [Related]
11. [Enhanced effect of intraperitoneal administration of CDDP combined with caffeine against peritoneal metastasis].
Yamamoto Y; Amano T; Imada T; Akaike M; Noguchi Y; Aoyama N; Tsuburaya A; Rino Y; Takehana T; Hasuo K
Gan To Kagaku Ryoho; 1991 Aug; 18(11):1825-31. PubMed ID: 1877825
[TBL] [Abstract][Full Text] [Related]
12. Para-aminobenzoic acid suppression of cis-diamminedichloroplatinum(II) nephrotoxicity.
Esposito M; Vannozzi MO; Viale M; Fulco RA; Collecchi P; Merlo F; De Cian F; Zicca A; Cadoni A; Poirier MC
Carcinogenesis; 1993 Dec; 14(12):2595-9. PubMed ID: 8269632
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of dibromodulcitol and BCNU in metastatic malignant melanoma.
Clamon G; Sinkey C; Jochimsen P
Am J Clin Oncol; 1985 Jun; 8(3):244-6. PubMed ID: 4050743
[TBL] [Abstract][Full Text] [Related]
14. Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.
Waud WR; Harrison SD; Gilbert KS; Laster WR; Griswold DP
Cancer Chemother Pharmacol; 1991; 27(6):456-63. PubMed ID: 1849465
[TBL] [Abstract][Full Text] [Related]
15. [Mechanism for synergistic antitumor effect in the combination of 5-fluorouracil with cisplatin in vivo tumor models: from the view of biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Ohshimo H; Kimura A; Fukushima M
Gan To Kagaku Ryoho; 1991 Mar; 18(3):403-9. PubMed ID: 2003740
[TBL] [Abstract][Full Text] [Related]
16. Identification of cisplatin sensitizers through high-throughput combinatorial screening.
Sun Y; Jiang W; Lu W; Song M; Liu K; Chen P; Chang A; Ling J; Chiao PJ; Hu Y; Huang P
Int J Oncol; 2018 Sep; 53(3):1237-1246. PubMed ID: 29956742
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of the activity of cisplatin and cyclophosphamide by trimidox, a novel ribonucleotide reductase inhibitor, in leukemia-bearing mice.
Novotny L; Rauko P; Liska J; Elford HL; Szekeres T
Cancer Lett; 2006 Feb; 233(1):178-84. PubMed ID: 15885888
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
19. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
20. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
Yang LY; Li L; Keating MJ; Plunkett W
Mol Pharmacol; 1995 May; 47(5):1072-9. PubMed ID: 7746274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
